|
|
(10.) The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients
|
1R21CA205636-01
|
$168,563
|
$84,282
|
CHEN, GRACE
|
UNIVERSITY OF MICHIGAN
|
|
|
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblasto
|
5R01CA190121-03
|
$332,000
|
$109,560
|
VERHAAK, ROELAND
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
1R01CA206025-01
|
$655,037
|
$655,037
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
1R21CA205644-01
|
$167,475
|
$167,475
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
1R01CA205967-01
|
$390,540
|
$390,540
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
|
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
|
1R01CA205101-01
|
$406,070
|
$406,070
|
SKALA, MELISSA
|
MORGRIDGE INSTITUTE FOR RESEARCH, INC.
|
|
|
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae
|
1R01CA208634-01
|
$560,277
|
$560,277
|
JURECIC, ROLAND
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle
|
7R21CA205437-02
|
$152,333
|
$152,333
|
WANING, DAVID
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle.
|
1R21CA205437-01
|
$51,247
|
$51,247
|
WANING, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQ9) Prevention of Bleomycin-induced Pulmonary Toxicity by Dichloroacetate (DCA)
|
1R21CA208746-01
|
$198,485
|
$198,485
|
KIM, JUNG-WHAN
|
UNIVERSITY OF TEXAS DALLAS
|
|
|
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
|
1R01CA205255-01
|
$577,463
|
$577,463
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INST
|
|
|
(PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiating cell maintenance
|
5R21CA194679-02
|
$160,885
|
$160,885
|
JAMIESON, CATRIONA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
|
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
|
5R01CA184922-03
|
$553,684
|
$276,842
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
|
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers
|
5R01CA184968-03
|
$509,161
|
$254,581
|
SIKIC, BRANIMIR
|
STANFORD UNIVERSITY
|
|
|
(PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodies
|
5R01CA185372-03
|
$321,937
|
$321,937
|
RICHARDS, KRISTY
|
CORNELL UNIVERSITY
|
|
|
(PQD5) Avatar-directed Treatment for Ovarian Cancer
|
5R01CA184502-03
|
$714,297
|
$714,297
|
WEROHA, SARAVUT
|
MAYO CLINIC ROCHESTER
|
|
|
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling
|
5R01CA185353-03
|
$405,890
|
$405,890
|
SHARPLESS, NORMAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
1/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
|
2U54CA156734-06A1
|
$1,746,493
|
$104,790
|
COLON-CARMONA, ADAN
|
UNIVERSITY OF MASSACHUSETTS BOSTON
|
|
|
1st International Symposium on Clinical and Experimental Metallodrugs in Medicine: Cancer Chemotherapy
|
1R13CA200223-01A1
|
$5,000
|
$5,000
|
CONTEL, MARIA
|
BROOKLYN COLLEGE
|
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-07
|
$997,277
|
$79,782
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
|
2U54CA156732-06A1
|
$1,905,807
|
$266,813
|
VISWANATH, KASISOMAYAJULA
|
DANA-FARBER CANCER INST
|
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
2U54CA118623-11
|
$1,134,399
|
$34,032
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
|
2016 Natural Products Gordon Research Conference
|
1R13CA206198-01
|
$4,000
|
$4,000
|
TAYLOR, RICHARD
|
GORDON RESEARCH CONFERENCES
|
|
|
2D and 3D Contrast-enhanced Ultrasound Evaluation of HCC Chemoembolization
|
1R01CA194307-01A1
|
$619,717
|
$619,717
|
EISENBREY, JOHN
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
3D Dynamic Contrast-Enhanced US for Monitoring Chemotherapy of Liver Metastasis
|
1R01CA195443-01A1
|
$255,216
|
$127,608
|
WILLMANN, JUERGEN
|
STANFORD UNIVERSITY
|
|
|
A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy
|
5R21CA179362-02
|
$202,928
|
$202,928
|
CUI, ZHENGRONG
|
UNIVERSITY OF TEXAS, AUSTIN
|
|
|
A functional genomics approach to determine the mechanism of cellular response to new anti-cancer drugs
|
1K99CA204602-01
|
$138,672
|
$138,672
|
GILBERT, LUKE
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
A network platform to connect drug response and prognosis phenotypes for cancers
|
1R01CA196631-01A1
|
$395,911
|
$395,911
|
LI, HU
|
MAYO CLINIC ROCHESTER
|
|
|
A New Small Molecule Targeted Therapeutic for Acute Myeloid Leukemia
|
1R43CA203172-01
|
$278,000
|
$278,000
|
MU, XUEYAN
|
TEAMEDON INTERNATIONAL, LLC
|
|
|
A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma
|
3R44CA159843-03S1
|
$94,422
|
$94,422
|
BALHORN, RODNEY
|
SHAL TECHNOLOGIES, INC.
|
|
|
A NOVEL EXTRACELLULAR AND INTRACELLULAR TREATMENT PARADIGM FOR ERADICATING CANCER
|
5F30CA189435-03
|
$30,079
|
$30,079
|
SOM, AVIK
|
WASHINGTON UNIVERSITY
|
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-02
|
$473,915
|
$236,958
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A novel strategy to overcome resistance in Temozolomide-Refractory Glioblastomas
|
5R21CA195149-02
|
$199,553
|
$199,553
|
HERGENROTHER, PAUL
|
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
|
|
|
A p53/NFkB-mediated metabolic mechanism for chemotherapy protection
|
5R01CA183074-03
|
$335,113
|
$335,113
|
YUAN, ZHI-MIN
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
|
|
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy
|
1R44CA206606-01
|
$995,814
|
$995,814
|
WILDS, DAN
|
CYNVEC, LLC
|
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-02
|
$618,770
|
$618,770
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning
|
5R01CA199137-02
|
$524,557
|
$173,104
|
AVIS, NANCY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
|
A Question Prompt List to Promote Communication in Genomic Medicine
|
1R21CA201827-01A1
|
$233,416
|
$116,708
|
O'NEILL, SUZANNE
|
GEORGETOWN UNIVERSITY
|
|
|
A Suite of Tumor Targeting Peptides for Personalized Therapy of Lung Cancer
|
5R01CA164447-06
|
$409,070
|
$409,070
|
BROWN, KATHLYNN
|
SRI INTERNATIONAL
|
|
|
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer
|
4R01CA168900-05
|
$332,000
|
$166,000
|
POWELL, DANIEL
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
|
4R01CA169519-04
|
$299,746
|
$299,746
|
SALVEMINI, DANIELA
|
SAINT LOUIS UNIVERSITY
|
|
|
AAAPT Technology for Improving Chemotherapy
|
3R43CA183353-01S1
|
$40,000
|
$40,000
|
PANDURANGI, RAGHU
|
SCI-ENGI-MEDCO SOLUTIONS, INC.
|
|
|
Aberrant signaling in acute myeloid leukemia
|
1R01CA204396-01A1
|
$459,674
|
$459,674
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Abramson Cancer Center Support Grant
|
2P30CA016520-40
|
$7,975,543
|
$558,288
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-40S1
|
$31,250
|
$2,188
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-40S2
|
$499,967
|
$34,998
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-40S3
|
$200,000
|
$14,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Activating Bax as a therapeutic strategy for lung cancer
|
4R01CA175003-04
|
$309,952
|
$309,952
|
LI, CHI
|
UNIVERSITY OF LOUISVILLE
|
|
|
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu
|
5U54CA190152-03
|
$699,897
|
$146,978
|
GOPAL, SATISH
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
Adipocytes are Important Players in the Acute Lymphoblastic Leukemia Microenvironment
|
1R01CA201444-01A1
|
$413,948
|
$413,948
|
MITTELMAN, STEVEN
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Total relevant funding to Chemotherapy for this search: $289,467,872
|
